Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy

University of Copenhagen

Status: Completed

Conditions: Muscle Hypertrophy in Healthy Young Men

Treatments: Drug: Placebo; Drug: Salbutamol; Other: Resistance training

Study type: Interventional

Funder types: Other

Identifiers

NCT02551276

SAL-STYRKE

Details and patient eligibility

About

Studies in animals have shown that beta2-adrenoceptor activation with selective agonists regulates protein metabolism and muscle growth in skeletal and cardiac muscle tissue. These effects may be mediated by cAMP/PKA dependent activation of several downstream sites that modulate protein synthesis and breakdown. While the role of beta2-adrenoceptor signaling is well-described in animals, it is inadequately explored in humans. The purpose of the study is thus to investigate the effect of chronic beta2-adrenergic stimulation (cAMP/PKA-signaling) on muscle hypertrophy.

Enrollment: 42 patients

Sex: Male

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Physical active
• Non-smokers
• Non-asthmatics
• No chronic diseases
• Informed consent

Exclusion criteria

• Smoker
• Allergy towards study drug

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

42 participants in 2 patient groups, including a placebo group

Experimental

Experimental group

Description:

Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks

Treatment:

Other: Resistance training

Drug: Salbutamol

Control

Placebo Comparator group

Description:

Placebo and resistance training for 10 weeks

Treatment:

Other: Resistance training

Drug: Placebo